A preclinical screen to evaluate pharmacotherapies for the treatment of agitation in dementia

Eugene O’Hare, Deaglan Page, William Curran, Jeong-Sup Hong, Eun-Mee Kim

Research output: Contribution to journalArticle

Abstract

Agitation associated with dementia is frequently reported
clinically but has received little attention in preclinical
models of dementia. The current study used a 7PA2 CM
intracerebroventricular injection model of Alzheimer’s
disease (AD) to assess acute memory impairment, and a
bilateral intrahippocampal (IH) injection model of AD
(aggregated Aβ1–42 injections) and a bilateral IH injection
model of dementia with Lewy bodies (aggregated NAC61–95
injections) to assess chronic memory impairment in the rat.
An alternating-lever cyclic-ratio schedule of operant
responding was used for data collection, where incorrect
lever perseverations measured executive function
(memory) and running response rates (RRR) measured
behavioral output (agitation). The results indicate that
bilateral IH injections of Aβ1–42 and bilateral IH injections of
NAC61–95 decreased memory function and increased RRRs,
whereas intracerebroventricular injections of 7PA2 CM
decreased memory function but did not increase RRRs.
These findings show that using the aggregated peptide IH
injection models of dementia to induce chronic
neurotoxicity, memory decline was accompanied by
elevated behavioral output. This demonstrates that IH
peptide injection models of dementia provide a preclinical
screen for pharmacological interventions used in the
treatment of increased behavioral output (agitation), which
also establish detrimental side effects on
memory
LanguageEnglish
Pages199-206
JournalBehavioural Pharmacology
Volume28
DOIs
Publication statusPublished - 1 Apr 2017

Fingerprint

Dementia
Drug Therapy
Injections
Therapeutics
Lewy Body Disease
Executive Function
Running
Appointments and Schedules
Pharmacology
Peptides

Keywords

  • agitation
  • Alzheimer's disease
  • animal model
  • dementia with Lewy bodies
  • memory
  • pharmacotherapy
  • rat

Cite this

O’Hare, Eugene ; Page, Deaglan ; Curran, William ; Hong, Jeong-Sup ; Kim, Eun-Mee. / A preclinical screen to evaluate pharmacotherapies for the treatment of agitation in dementia. In: Behavioural Pharmacology. 2017 ; Vol. 28. pp. 199-206.
@article{0333d2a95e0e4b1785d8287927db15f8,
title = "A preclinical screen to evaluate pharmacotherapies for the treatment of agitation in dementia",
abstract = "Agitation associated with dementia is frequently reportedclinically but has received little attention in preclinicalmodels of dementia. The current study used a 7PA2 CMintracerebroventricular injection model of Alzheimer’sdisease (AD) to assess acute memory impairment, and abilateral intrahippocampal (IH) injection model of AD(aggregated Aβ1–42 injections) and a bilateral IH injectionmodel of dementia with Lewy bodies (aggregated NAC61–95injections) to assess chronic memory impairment in the rat.An alternating-lever cyclic-ratio schedule of operantresponding was used for data collection, where incorrectlever perseverations measured executive function(memory) and running response rates (RRR) measuredbehavioral output (agitation). The results indicate thatbilateral IH injections of Aβ1–42 and bilateral IH injections ofNAC61–95 decreased memory function and increased RRRs,whereas intracerebroventricular injections of 7PA2 CMdecreased memory function but did not increase RRRs.These findings show that using the aggregated peptide IHinjection models of dementia to induce chronicneurotoxicity, memory decline was accompanied byelevated behavioral output. This demonstrates that IHpeptide injection models of dementia provide a preclinicalscreen for pharmacological interventions used in thetreatment of increased behavioral output (agitation), whichalso establish detrimental side effects onmemory",
keywords = "agitation, Alzheimer's disease, animal model, dementia with Lewy bodies, memory, pharmacotherapy, rat",
author = "Eugene O’Hare and Deaglan Page and William Curran and Jeong-Sup Hong and Eun-Mee Kim",
note = "UIR Compliant - evidence uploaded to other files",
year = "2017",
month = "4",
day = "1",
doi = "10.1097/FBP.0000000000000298",
language = "English",
volume = "28",
pages = "199--206",
journal = "Behavioural Pharmacology",
issn = "0955-8810",

}

A preclinical screen to evaluate pharmacotherapies for the treatment of agitation in dementia. / O’Hare, Eugene; Page, Deaglan; Curran, William; Hong, Jeong-Sup; Kim, Eun-Mee.

In: Behavioural Pharmacology, Vol. 28, 01.04.2017, p. 199-206.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A preclinical screen to evaluate pharmacotherapies for the treatment of agitation in dementia

AU - O’Hare, Eugene

AU - Page, Deaglan

AU - Curran, William

AU - Hong, Jeong-Sup

AU - Kim, Eun-Mee

N1 - UIR Compliant - evidence uploaded to other files

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Agitation associated with dementia is frequently reportedclinically but has received little attention in preclinicalmodels of dementia. The current study used a 7PA2 CMintracerebroventricular injection model of Alzheimer’sdisease (AD) to assess acute memory impairment, and abilateral intrahippocampal (IH) injection model of AD(aggregated Aβ1–42 injections) and a bilateral IH injectionmodel of dementia with Lewy bodies (aggregated NAC61–95injections) to assess chronic memory impairment in the rat.An alternating-lever cyclic-ratio schedule of operantresponding was used for data collection, where incorrectlever perseverations measured executive function(memory) and running response rates (RRR) measuredbehavioral output (agitation). The results indicate thatbilateral IH injections of Aβ1–42 and bilateral IH injections ofNAC61–95 decreased memory function and increased RRRs,whereas intracerebroventricular injections of 7PA2 CMdecreased memory function but did not increase RRRs.These findings show that using the aggregated peptide IHinjection models of dementia to induce chronicneurotoxicity, memory decline was accompanied byelevated behavioral output. This demonstrates that IHpeptide injection models of dementia provide a preclinicalscreen for pharmacological interventions used in thetreatment of increased behavioral output (agitation), whichalso establish detrimental side effects onmemory

AB - Agitation associated with dementia is frequently reportedclinically but has received little attention in preclinicalmodels of dementia. The current study used a 7PA2 CMintracerebroventricular injection model of Alzheimer’sdisease (AD) to assess acute memory impairment, and abilateral intrahippocampal (IH) injection model of AD(aggregated Aβ1–42 injections) and a bilateral IH injectionmodel of dementia with Lewy bodies (aggregated NAC61–95injections) to assess chronic memory impairment in the rat.An alternating-lever cyclic-ratio schedule of operantresponding was used for data collection, where incorrectlever perseverations measured executive function(memory) and running response rates (RRR) measuredbehavioral output (agitation). The results indicate thatbilateral IH injections of Aβ1–42 and bilateral IH injections ofNAC61–95 decreased memory function and increased RRRs,whereas intracerebroventricular injections of 7PA2 CMdecreased memory function but did not increase RRRs.These findings show that using the aggregated peptide IHinjection models of dementia to induce chronicneurotoxicity, memory decline was accompanied byelevated behavioral output. This demonstrates that IHpeptide injection models of dementia provide a preclinicalscreen for pharmacological interventions used in thetreatment of increased behavioral output (agitation), whichalso establish detrimental side effects onmemory

KW - agitation

KW - Alzheimer's disease

KW - animal model

KW - dementia with Lewy bodies

KW - memory

KW - pharmacotherapy

KW - rat

U2 - 10.1097/FBP.0000000000000298

DO - 10.1097/FBP.0000000000000298

M3 - Article

VL - 28

SP - 199

EP - 206

JO - Behavioural Pharmacology

T2 - Behavioural Pharmacology

JF - Behavioural Pharmacology

SN - 0955-8810

ER -